Anti CD38 monoclonal antibodies for multiple myeloma treatment

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–9. doi:10.3322/caac.21654. PMID 33433946
   PubMed Web of Science ®Google Scholar
• Gozzetti A, Le Beau MM. Fluorescence in situ hybridization: uses and limitations. Semin Hematol. 2000;37(4):320–33. doi:10.1016/s0037-1963(00)90013-1. PMID:11071355
   PubMed Web of Science ®Google Scholar
• Gozzetti A, Candi V, Papini G, Bocchia M. Therapeutic advancements in multiple myeloma. Front Oncol. 2014;4:241. doi:10.3389/fonc.2014.00241. PMID: 25237651
   PubMedGoogle Scholar
• Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014;28(3):525–42. doi:10.1038/leu.2013.350. PMID: 24253022
   PubMed Web of Science ®Google Scholar
• Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, et al. EMMOS investigators. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clin Lymphoma Myeloma Leuk. 2018;18(10):e401–e419. doi:10.1016/j.clml.2018.06.018. PMID: 30030033
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–20. doi:10.1182/blood-2007-10-116129. PMID: 17975015
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, et al. IgM myeloma: a multicenter retrospective study of 134 patients. Am J Hematol. 2017;92(8):746–51. doi:10.1002/ajh.24753. PMID: 28383205
   PubMed Web of Science ®Google Scholar
• Gozzetti A, Cerase A. Novel agents in CNS myeloma treatment. Cent Nerv Syst Agents Med Chem. 2014;14(1):23–27. doi:10.2174/1871524914999140818111514. PMID: 25134940
   PubMedGoogle Scholar
• Gozzetti A, Cerase A, Lotti F, Rossi D, Palumbo A, Petrucci MT, Patriarca F, Nozzoli C, Cavo M, Offidani M, et al. GIMEMA (Gruppo Italiano Malattie Ematologiche dell’adulto) myeloma working party. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer. 2012 Mar 15; 118(6):1574–84. 10.1002/cncr.26447. Epub 2011 Aug 25. PMID: 21932386
   PubMed Web of Science ®Google Scholar
• Kocoglu MH, Badros AZ. Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond. Expert Rev Hematol. 2020 ;13(6):669–86. doi:10.1080/17474086.2020.1756258. PMID: 32290719.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 ;17(8):e328–e346. doi:10.1016/S1470-2045(16)30206-6. PMID: 27511158
   PubMed Web of Science ®Google Scholar
• Gozzetti A, Raspadori D, Bacchiarri F, Sicuranza A, Pacelli P, Ferrigno I, Tocci D, Bocchia M. Minimal residual disease in multiple myeloma: state of the art and applications in clinical practice. J Pers Med. 2020 Sep 10;10(3):120. 10.3390/jpm10030120. PMID: 32927719; PMCID: PMC7565263
   PubMed Web of Science ®Google Scholar
• Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K. Human CD38: a glycoprotein in search of a function. Immunol Today. 1994 ;15(3):95–97. doi:10.1016/0167-5699(94)90148-1. PMID: 8172650.
   PubMedGoogle Scholar
• Funaro A, Reinis M, Trubiani O, Santi S, Di Primio R, Malavasi F. CD38 functions are regulated through an internalization step. J Immunol. 1998 Mar 1;160(5):2238–47. PMID: 9498763
   PubMed Web of Science ®Google Scholar
• Funaro A, Horenstein AL, Calosso L, Morra M, Tarocco RP, Franco L, De Flora A, Malavasi F. Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids. Int Immunol. 1996 ;8(11):1643–50. doi:10.1093/intimm/8.11.1643. PMID: 8943558.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res. 2001;25(1):1–12. doi:10.1016/S0145-2126(00)00093-X.
   PubMed Web of Science ®Google Scholar
• Cyster JG. Homing of antibody secreting cells. Immunol Rev. 2003;194(1):48–60. doi:10.1034/j.1600-065X.2003.00041.x.
   PubMed Web of Science ®Google Scholar
• Prosper F, Stroncek D, Verfaillie CM. Phenotypic and functional characterization of long-term culture-initiating cells present in peripheral blood progenitor collections of normal donors treated with granulocyte colony-stimulatingfactor. Blood. 1996;88(6):2033–42. doi:10.1182/blood.V88.6.2033.bloodjournal8862033.
   PubMed Web of Science ®Google Scholar
• Lee HC, Zocchi E, Guida L, Franco L, Benatti U, De Flora A. Production and hydrolysis of cyclic ADP-ribose at the outer surface of human erythrocytes. Biochem Biophys Res Commun. 1993 Mar 15;191(2):639–45. 10.1006/bbrc.1993.1265. PMID: 8461019
   PubMed Web of Science ®Google Scholar
• Zocchi E, Franco L, Guida L, Benatti U, Bargellesi A, Malavasi F, Lee HC, De Flora A. A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. Biochem Biophys Res Commun. 1993 Nov 15;196(3):1459–65. 10.1006/bbrc.1993.2416. PMID: 8250903
   PubMed Web of Science ®Google Scholar
• Ramaschi G, Torti M, Festetics ET, Sinigaglia F, Malavasi F, Balduini C. Expression of cyclic ADP-ribose-synthetizing CD38 molecule on human platelet membrane. Blood. 1996 Mar 15;87(6):2308–13. PMID: 8630392. 10.1182/blood.V87.6.2308.bloodjournal8762308
   PubMed Web of Science ®Google Scholar
• Xu Y, McKenna RW, Asplund SL, Kroft SH. Comparison of immunophenotypes of small B-cell neoplasms in primary lymph node and concurrent blood or marrow samples. Am J Clin Pathol. 2002 ;118(5):758–64. doi:10.1309/11J6-0U42-VF4E-WA02. PMID: 12428797.
   PubMed Web of Science ®Google Scholar
• Keyhani A, Huh YO, Jendiroba D, Pagliaro L, Cortez J, Pierce S, Pearlman M, Estey E, Kantarjian H, Freireich EJ. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk Res. 2000 ;24(2):153–59. doi:10.1016/s0145-2126(99)00147-2. PMID: 10654451.
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Vergilio JA, Shahsafaei A, Dorfman DM. Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. Am J Surg Pathol. 2008 ;32(1):113–22. doi:10.1097/PAS.0b013e3180959e09. PMID: 18162778.
   PubMed Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NW, Weiss BM, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016 Jul 21; 128(3):384–94. 10.1182/blood-2015-12-687749. Epub 2016 May 24. PMID: 27222480
   PubMed Web of Science ®Google Scholar
• Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, Vaisitti T, Aydin S. Evolution and function of the ADP ribosyl cyclase/cd38 gene family in physiology and pathology. Physiol Rev. 2008 ;88(3):841–86. doi:10.1152/physrev.00035.2007.
   PubMed Web of Science ®Google Scholar
• Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004 ;121(4):482–88. doi:10.1309/74R4-TB90-BUWH-27JX.
   PubMed Web of Science ®Google Scholar
• Lee HC. Structure and enzymatic functions of human CD38. Mol Med. 2006;12(11–12):317–23. doi:10.2119/2006-00086.Lee.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999 Sep 15;94(6):1840–47. PMID: 10477712. 10.1182/blood.V94.6.1840
   PubMed Web of Science ®Google Scholar
• Chini EN, Chini CC, Kato I, Takasawa S, Okamoto H. CD38 is the major enzyme responsible for synthesis of nicotinic acid-adenine dinucleotide phosphate in mammalian tissues. Biochem J. 2002 Feb 15;362(Pt 1):125–30. 10.1042/0264-6021:3620125. PMID: 11829748
   PubMedGoogle Scholar
• Howard M, Grimaldi JC, Bazan JF, Lund FE, Santos-Argumedo L, Parkhouse RM, Walseth TF, Lee HC. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science. 1993 Nov 12;262(5136):1056–59. 10.1126/science.8235624. PMID: 8235624
   PubMed Web of Science ®Google Scholar
• Takasawa S, Tohgo A, Noguchi N, Koguma T, Nata K, Sugimoto T, Yonekura H, Okamoto H. Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP. J Biol Chem. 1993 Dec 15;268(35):26052–54.
   PubMed Web of Science ®Google Scholar
• Barr H, Dempsey J, Waller A, Huang Y, Williams N, Sharma N, Benson DM, Rosko AE, Efebera YA, Hofmeister CC Ninety-Minute daratumumab infusion is safe in multiple myeloma. Leukemia. 2018;32(11):2495–518. doi:10.1038/s41375-018-0120-2. Epub 2018 Mar 31. PMID: 29679038.
   PubMed Web of Science ®Google Scholar
• Gozzetti A, Bacchiarri F, Sammartano V, Defina M, Sicuranza A, Mecacci B, Zappone E, Cencini E, Fabbri A, Raspadori D, et al. Long-term safety of rapid Daratumumab infusions in multiple myeloma patients. Front Oncol. 2020;10:570187. doi:10.3389/fonc.2020.570187. PMID: 33415072.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Bögels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, Groen RW, Breij E, Martens AC, Bleeker WK, et al. Antibody-Mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. Mabs. 2015;7(2):311–21. doi:10.1080/19420862.2015.1007813. PMID: 25760767.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Jansen JH, Nederend M, van Bueren JJ L, Groen RW, Parren PW, Leusen JH, Boross P. The therapeutic CD38 monoclonal antibody Daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking. J Immunol. 2016 Aug 1;197(3):807–13. 10.4049/jimmunol.1501351. Epub 2016 Jun 17. PMID: 27316683
   PubMed Web of Science ®Google Scholar
• van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, Lokhorst HM, Mutis T The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J. 2011 ;1(10):e41. doi:10.1038/bcj.2011.42. Epub 2011 Oct 28. PMID: 22829073.
   PubMed Web of Science ®Google Scholar
• Busch L, Mougiakakos D, Büttner-Herold M, Müller MJ, Volmer DA, Bach C, Fabri M, Bittenbring JT, Neumann F, Boxhammer R, et al. Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway. Leukemia. 2018 ;32(11):2445–58. 10.1038/s41375-018-0114-0. Epub 2018 Mar 28. PMID: 29654274
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, et al. Targeting CD38 with Daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015 Sep 24;373(13):1207–19. 10.1056/NEJMoa1506348. Epub 2015 Aug 26. PMID: 26308596
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016 Jul 7;128(1):37–44. 10.1182/blood-2016-03-705210. Epub 2016 May 23. PMID: 27216216; PMCID: PMC4937359
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, Voorhees PM, Laubach JP, van de Donk NWCJ, Ahmadi T, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020 ;7(6):e447–e455. 10.1016/S2352-3026(20)30081-8. PMID: 32470437
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, et al. POLLUX investigators. Daratumumab, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med. 2016 Oct 6;375(14):1319–31. 10.1056/NEJMoa1607751. PMID: 27705267
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, et al. CASTOR investigators. Daratumumab, Bortezomib, and Dexamethasone for multiple myeloma. N Engl J Med. 2016 Aug 25;375(8):754–66. 10.1056/NEJMoa1606038. PMID: 27557302
   PubMed Web of Science ®Google Scholar
• Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017 Aug 24;130(8):974–81. 10.1182/blood-2017-05-785246. Epub 2017 Jun 21. PMID: 28637662; PMCID: PMC5570682
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020 ;396(10245):186–97. doi:10.1016/S0140-6736(20)30734-0. Erratum in: Lancet. 2020 Aug 15;396(10249):466. PMID: 32682484
   PubMed Web of Science ®Google Scholar
• Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019 ;394(10192):29–38. doi:10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3. Erratum in: Lancet. 2019 Jun 14; PMID: 31171419
   PubMed Web of Science ®Google Scholar
• Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020 Jan 11;395(10218):132–41. 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10. PMID: 31836199
   PubMed Web of Science ®Google Scholar
• Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020 ;7(5):e370–e380. 10.1016/S2352-3026(20)30070-3. Epub 2020 Mar 23
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, et al. APOLLO trial investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 ;22(6):801–12. 10.1016/S1470-2045(21)00128-5. PMID: 34087126
   PubMed Web of Science ®Google Scholar
• Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, et al. MAIA trial investigators. Daratumumab plus Lenalidomide and Dexamethasone for untreated myeloma. N Engl J Med. 2019 May 30;380(22):2104–15. 10.1056/NEJMoa1817249. PMID: 31141632
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Ld A Jr, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 Aug 20;136(8):936–45. 10.1182/blood.2020005288. PMID: 32325490
   PubMed Web of Science ®Google Scholar
• Mateos MV, Kumar S, Dimopoulos MA, González-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, et al. International myeloma working group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020 Oct 16;10(10):102. 10.1038/s41408-020-00366-3. PMID: 33067414; PMCID: PMC7567803
   PubMed Web of Science ®Google Scholar
• Landgren CO, Chari A, Cohen YC, Spencer A, Voorhees P, Estell JA, Sandhu I, Jenner MW, Williams C, Cavo M, et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2020 ;34(7):1840–52. 10.1038/s41375-020-0718-z. Epub 2020 Feb 5. PMID: 32024950; PMCID: PMC7326703
   PubMed Web of Science ®Google Scholar
• Janssen. DARZALEX® (daratumumab) injection, for intravenous use [package insert]; [ accessed 2021 Nov] https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf
   Google Scholar
• Zhu C, Song Z, Wang A, Srinivasan S, Yang G, Greco R, Theilhaber J, Shehu E, Wu L, Yang ZY, et al. Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells. Front Immunol. 2020 Aug 14;11:1771. 10.3389/fimmu.2020.01771. PMID: 32922390; PMCID: PMC7457083
   PubMed Web of Science ®Google Scholar
• Feng X, Zhang L, Acharya C, An G, Wen K, Qiu L, Munshi NC, Tai YT, Anderson KC. Targeting CD38 suppresses induction and function of T Regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017 Aug 1;23(15):4290–300. 10.1158/1078-0432.CCR-16-3192. Epub 2017 Mar 1. PMID: 28249894; PMCID: PMC5540790
   PubMed Web of Science ®Google Scholar
• Song Z, Yang G, Wang A, Greco R, Theilhaber J, Shehu E, Ajona D, Paiva B, Zhu C, Wiederschain D et al. Isatuximab-Induced multiple myeloma cell killing through effector functions is dependent on CD38 expression and complement inhibitors. Cancer Res. 2019;79:13 Supplement.
   Web of Science ®Google Scholar
• Jiang H, Acharya C, An G, Zhong M, Feng X, Wang L, Dasilva N, Song Z, Yang G, Adrian F, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016 ;30(2):399–408. 10.1038/leu.2015.240. Epub 2015 Sep 4. PMID: 26338273
   PubMed Web of Science ®Google Scholar
• Tai YT, Anderson KC. Targeting CD38 alleviates tumor-induced immunosuppression. Oncotarget. 2017 Dec 26;8(68):112166–67. 10.18632/oncotarget.22992. PMID: 29348814; PMCID: PMC5762499
   PubMedGoogle Scholar
• SanofI-Aventis. SARCLISA (isatuximab): EU summary of product characteristics; 2021 [accessed 2021 Apr 22]. https://www.ema.europa.eu
   Google Scholar
• SanofI-Aventis. SARCLISA® (isatuximab-irfc): US prescribing information; 2021 [accessed 2021 Apr 22]. https://www.fda.gov/drugs
   Google Scholar
• Martin T, Strickland S, Glenn M, Charpentier E, Guillemin H, Hsu K, Mikhael J. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. Blood Cancer J. 2019 Mar 29;9(4):41. 10.1038/s41408-019-0198-4. PMID: 30926770; PMCID: PMC6440961
   PubMedGoogle Scholar
• Mikhael J, Richardson P, Usmani SZ, Raje N, Bensinger W, Karanes C, Campana F, Kanagavel D, Dubin F, Liu Q, et al. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood. 2019 Jul 11;134(2):123–33. 10.1182/blood-2019-02-895193. Epub 2019 Mar 12. PMID: 30862646; PMCID: PMC6659612
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Karanes C, Bensinger WI, D’-Souza A, Raje N, Tuchman SA, Sborov D, Laubach JP, Bianchi G, Kanagavel D, et al. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia. 2021 May 28. 10.1038/s41375-021-01262-w. Epub ahead of print. PMID: 34050260
   Web of Science ®Google Scholar
• Martin TG, Shah N, Richter J, Vesole DH, Wong SW, Huang CY, Madduri D, Jagannath S, Siegel DS, Biran N, et al. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. Cancer. 2021 Jun 1;127(11):1816–26. 10.1002/cncr.33448. Epub 2021 Mar 18. PMID: 33735504; PMCID: PMC8252002
   PubMed Web of Science ®Google Scholar
• Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, Lesokhin AM, Wack C, Charpentier E, Campana F, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017 Jun 22;129(25):3294–303. 10.1182/blood-2016-09-740787. Epub 2017 May 8. PMID: 28483761; PMCID: PMC5482100
   PubMed Web of Science ®Google Scholar
• Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, et al; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Dec 7;394(10214):2096–107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Erratum in: Lancet. 2019 Dec 7;394(10214):2072. PMID: 31735560.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Leleu X, Moreau P, Richardson PG, Liberati AM, Harrison SJ, Miles Prince H, Ocio EM, Assadourian S, Campana F, et al. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia. 2021 ;35(2):562–72. 10.1038/s41375-020-0868-z. PMID: 32444867; PMCID: PMC7862055
   PubMed Web of Science ®Google Scholar
• Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, et al. IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021 Jun 19;397(10292):2361–71. 10.1016/S0140-6736(21)00592-4. PMID: 34097854
   PubMed Web of Science ®Google Scholar
• Boxhammer R, Weirather J, Steidl S, Endell J. MOR202, a human anti-CD38 monoclonal antibody, mediates potent tumoricidal activity in vivo and shows synergistic efficacy in combination with different antineoplastic compounds. Blood. 2015;126:3015.
   Web of Science ®Google Scholar
• Raab MS, Engelhardt M, Blank A, Goldschmidt H, Agis H, Blau IW, Einsele H, Ferstl B, Schub N, Röllig C, et al. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Lancet Haematol. 2020 ;7(5):e381–e394. 10.1016/S2352-3026(19)30249-2. PMID: 32171061
   PubMed Web of Science ®Google Scholar
• Krishnan AY, Patel KK, Hari P, Jagannath S, Niesvizky R, Silbermann RW, Berg DT, Li Q, Allikmets K, Stockerl-Goldstein K. A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/refractory multiple myeloma (RRMM): preliminary results. J Clin Oncol 2020;38. doi:10.1200/JCO.2020.38.15_suppl.8539. Abstract #8539
   Web of Science ®Google Scholar